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Preliminary in vitro evaluation of the anti-proliferative activity 
of guanylhydrazone derivatives
Guanylhydrazones have shown promising antitumor 
activity in preclinical tumor models in several studies. 
In this study, we aimed at evaluating the cytotoxic eff ect 
of a series of synthetic guanylhydrazones. Diff erent hu-
man tumor cell lines, by including HCT-8 (colon carci-
noma), MDA-MB-435 (melanoma) and SF-295 (glioblas-
toma) were continuous exposed to guanylhydrazone 
derivatives for 72 hours and growth inhibition of tumor 
cell lines and macrophages J774 was measured using tet-
razolium salt (MTT) assay. Compounds 7, 11, 16 and 17 
showed strong cytotoxic activity with IC50 values lower 
than 10 μmol L–1 against four tumor cell lines. Among 
them, 7 was less toxic to non-tumor cells. Finally, ob-
tained data suggest that guanylhydrazones may be re-
garded as potential lead compounds for the design of 
novel anticancer agents.
Keywords: guanylhydrazone, cytotoxic eff ect, synthesis, 
MTT assay
PAULO H. B. FRANÇA2
EDEILDO F. DA SILVA-JÚNIOR2
PEDRO G. V. AQUINO1
ANTÔNIO E. G. SANTANA1
JAMYLLE N. S. FERRO3
EMILIANO DE OLIVEIRA BARRETO3
CLÁUDIA DO Ó PESSOA4
ASSUERO SILVA MEIRA4
THIAGO M. DE AQUINO2
MAGNA S. ALEXANDRE-MOREIRA5
MARTINE SCHMITT6
JOÃO X. DE ARAÚJO-JÚNIOR2*
1 Natural Resources Research Laboratory
Institute of Chemistry and Biotechnology
Federal University of Alagoas, Maceio, Brazil
2 Laboratory of Medicinal Chemistry
School of Nursing and Pharmacy
Federal University of Alagoas, Maceio, Brazil
3 Cell Biology Laboratory, Biological and 
Health Sciences, Federal University of 
Alagoas, Maceio, Brazil
4 Experimental Oncology Laboratory 
Department of Physiology and Pharmacology
Federal University of Ceara, Fortaleza, Brazil
5 Institute of Biological and Health Sciences
Laboratory of Pharmacology and Immunity
Federal University of Alagoas, Maceio, Brazil
6 Laboratoire d’innovation Thérapeutique
Faculté de Pharmacie, Université de Strasbourg
Illkirck, France
Accepted November 25, 2015
Online published February 11, 2016
* Correspondence; e-mail: jotaaranjo2004@gmail.com
130
P. H. B. França et al.: Preliminary in vitro evaluation of the anti-proliferative activity of guanylhydrazone derivatives, Acta Pharm. 66 
(2016) 129–137.
 
Guanylhydrazones represent a class of compounds showing interesting pharmaco-
logical activities on several levels; they derive from the same aminoguanidine chemotype 
with mixed hydrogen bond acceptor and donor properties as well as being able to establish 
electrostatic interactions (1, 2). Moreover, they already led to various active derivatives, as 
illustrated in Fig. 1 (3). Guanidine derivatives have been reported to be effi  cient anti-cancer 
agents. Previous reports showed that m-iodobenzylguanidines (MIBG), pyridylcyanogua-
nidine (CHS 828) and mitoguazone (MGBG) have shown promising antitumor activity in 
preclinical tumor models, while mitoguazone showed useful clinical activity for the treat-
ment of malignant lymphoma, carcinoma of the head, neck and esophageal and non-small 
cell lung cancer (4). More recently, a series of imidazo[2,1-b]thiazoleguanylhydrazones was 
reported for their antitumor activity and was able to induce apoptosis in HT29 and HL-60 
cell lines (5). However, no structure-activity relationship of imidazothiazole compounds 
was available. Sixteen guanylhydrazone coactivator binding inhibitors for estrogen recep-
tor showed good to moderate activity, but no cytotoxicity data were shown for these com-
pounds (6).
Fig. 1. Cytotoxic guanylhydrazones previously reported in literature (4).
Aft er identifi cation of the guanidine moiety, as the key pharmacophoric group for activ-
ity, we decided to replace the imidazothiazole ring by a phenyl ring, which off ered the ad-
vantage of scaff old modifi cation. In particular, our objective was to perform a systematic 
exploration of the aryl group allowing introduction of various substituents at the phenyl 
ring. The phenyl ring was replaced by heteroaromatics in another series of compounds.
EXPERIMENTAL
General
All purchased chemical reagents (Sigma-Aldrich, Brazil) were of the highest purity. 
Thin layer chromatography was done on aluminum sheets (DC Silicagel 60, Merck, Brazil) 
and observed under ultraviolet light at 254 and 366 nm in a Spectroline® ENF-260 CIF 
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chamber. NMR spectra (1H: 400 MHz; 13C: 100 MHz) were obtained from a Bruker® DPX 
500 (Germany) device. All chemical shift  values were recorded as d (ppm), the coupling 
constant value J was measured in hertz; the peaks are presented as s (singlet), d (doublet), 
t (triplet), dd (double doublet), and m (multiplet).
Synthesis of target compounds
Guanylhydrazones 1-20 were prepared by the reaction of an appropriate aryl alde-
hyde with aminoguanidine hydrochloride (1:1.25 equiv). The reactants were dissolved in 
a minimal amount of methanol, heated to refl ux, and stirred overnight. Upon cooling to 
room temperature, products crystallized out from the methanol solution. Products were 
recovered and dried under vacuum overnight. All reactions were monitored by TLC. The 
solvent was removed under reduced pressure and the solid was triturated with ethyl ac-
etate yielding the substances as powders.
Assessment of cell viability
Cytotoxic eff ects of the synthesized compounds were evaluated against the following 
human cancer cell lines (National Cancer Institute, Bethesda, MD, USA): HCT-8 (colon 
carcinoma), SF-295 (glioblastoma) and MDA-MB-435 (melanoma). Tumor cells were seeded 
in 96-well plates (0.7 × 105 cells per well for adherent cells and 3 × 105 cells mL–1 for sus-
pended cells). Aft er 24 hours, the compounds (5 mg mL–1), dissolved in dimethylsulfoxide 
(DMSO), were added to each well using an automated workstation Biomek® 3000 (Beck-
man Coulter, USA) and incubated for 72 hours. Addition of doxorubicin (Sigma Aldrich 
Co., USA) at 5 mg mL–1 concentrations was performed in 150 mL of Roswell Park Memorial 
Institute (RPMI 1640) medium [2 mmol L–1 of L-glutamine, 10 mmol L–1 of 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 1 mmol L–1 of sodium pyruvate, 4.5 g L–1 of glu-
cose, 1500 mg L–1 of sodium bicarbonate, 0.5 mg mL–1 MTT]. Aft er 3 hours, the formazan 
product was dissolved in 150 mL DMSO and the absorbance was measured using a multi-
plate reader (DTX 880 Multimode Detector, Beckman Coulter). The substance eff ect was 
quantifi ed as the percentage of control absorbance at 595 nm.
Macrophage J774 cells were seeded (105 cells per well) in 96-well fl at-bott om micro-
plates. The cells were maintained for 2 hours at 37 °C, 5 % CO2 and the medium was re-
placed with diff erent concentrations of the drugs (10, 100 and 1000 mmol L–1), in duplicate, 
and exposed for another 24 hours. Growth controls were also included. Aft erwards, MTT 
solution was added to the cells and plates were returned to the incubator for another 4 
hours to evaluate cell viability. This was followed by washing of the wells with 150 mL of 
DMSO for 15 minutes and measurement was performed spectrophotometrically at 540 nm.
RESULTS AND DISCUSSION
Guanylhydrazone derivatives were obtained through the condensation reaction of 
benzaldehyde derivatives with aminoguanidine hydrochloride (7, 8; see Scheme 1).
All compounds were characterized by hydrogen (¹H) and carbon (¹³C) NMR. The 
main chemical shift s for each compound are shown in Table I. A signal at d 7.27 to 9.05 ppm 
in 1H NMR spectra of all synthesized substances could be observed and was att ributed to 
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Table I. Spectral data of guanylhydrazones
 Compd. ¹H NMR (δ, ppm, Hz) ¹³CNMR (δ, ppm) 
  1 7.12 (t, 1H, J = 7.2), 7.19 (t, 1H, J = 7.2), 7.45 (d, 1H, J = 7.2), 7.8 (s, 1H), 8.28 (d, 1H, J = 7.2), 8.36 (s, 1H)
121.23, 122.75, 123.27, 124.31, 132.24, 
137.51, 145.35, 155.20
  2 7.45 (d, 2H, J = 8.5), 7.85 (d, 2H, J = 8.5), 8.15 (s, 1H)
129.23, 129.70, 132.81, 135.43, 146.01, 
155.83
  3 7.87 (d, 2H, J = 8.5), 8.04 (d, 2H, J = 8.5), 8.24 (s, 1H)
112.67, 119.11, 128.60, 133.02, 138.30, 
145.36, 155.89
  4 3.79 (s, 3H), 6.95 (d, 1H, J = 8,3), 7.18 (dd, 1H, J = 8.3 and 2.0), 7.33 (d, 1H, J = 2.0), 8.04 (s, 1H)
56.11, 112.05, 113.81, 121.09, 126.63, 147.06, 
147.62, 150.49, 155.61
  5 3.80 (s, 6H), 6.97 (d, 1H, J = 7.9), 7.23 (d, 1H, J = 7.9), 7.54 (s, 1H), 8.09 (s, 1H)
109.17, 111.60, 123.09, 126.53, 147.39, 149.51, 
151.47, 155.63, 155.70, 156.16
  6 3.81 (s, 3H), 6.83 (d, 1H, J = 8.0); 7.13 (dd, 1H, J = 8.0 and 1.8), 7.50 (s, 1H), 8.04 (s, 1H)
56.24, 110.08, 115.67, 123.18, 125.22, 147.74, 
148.51, 149.78, 155.52
  7 6.83 (d, 2H, J = 8.5), 7.66 (d, 2H, J = 8.5),8.06 (s, 1H)
116.06, 124.79, 129.85, 147.52, 155.62, 
160.28
  8 7.63 (d, 2H, J = 8.5), 7.81 (d, 2H, J = 8.5), 8.17 (s, 1H) 124.31, 129.93, 132.15, 133.15, 146.11, 155.79
  9 6.05 (s, 2H), 6.94 (d, 1H, J = 8.0), 7.17 (dd, 1H, J = 8.0 and 1.6), 7.64 (d, 1H, J =1.6), 8.07 (s, 1H)
102.03, 105.94, 108.65, 124.80, 128.37, 
146.83, 148.45, 149.80, 155.74
10 1.38 (s, 18H), 7.50 (s, 2H), 8.09 (s, 1H) 30.69, 35.01, 124.99, 139.66, 148.96, 155.53, 156.98
11 7.90 (s, 4H), 8.20 (s, 1H) 128.07, 130.01, 132.45, 137.86, 146.18, 155.84, 167.36
12 7.45 (m, 1H), 7.57 (d, 2H, J = 7.9), 8.42 (s, 1H) 129.56, 130.01, 132.18, 134.53, 142.99, 155.78
13 7.72 (t, 1H, J = 7.5), 7.84 (t, 1H, J = 7.5), 8.09 119.08, 123.89, 125.31, 128.12, 130.14
(d, 1H, J = 8.2), 8.40 (d, 1H, J = 8.2), 8.18 (d, 1H, 
J = 4.3), 8.98 (d, 1H, J = 4.3), 9.05 (s, 1H) 130.29, 137.09, 143.47, 148.70, 150.61, 155.77
14 7.47 (m, 5H), 7.74 (d, 2H, J = 8.4), 7.94 (d, 2H, J = 8.4), 8.24 (s, 1H)
127.20, 127.35, 128.44, 128.68, 129.51, 
132.94, 139.68, 142.41, 146.95, 155.79
15 7.43 (m, 3H), 7.84 (m, 2H), 8.19 (s, 1H) 128.03, 129.17, 130.99, 133.81, 147.35, 155.80
16 3.84 (s, 3H), 7.98 (s, 4H), 8.25 (s, 1H) 2.79, 128.19, 129.87, 131.21, 138.25, 146.08, 155.82, 166.30
17 7.68 (d, 1H, J = 8.4), 7.79 (dd, 1H, J = 8.4 and 2.0), 8.24 (d, 1H, J = 2.0), 8.16 (s, 1H)
128.45, 129.02, 131.33, 132.25, 133.13, 
134.66, 144.75, 155.81
18 7.47 (m, 2H), 7.74 (d, 1H, J = 8.0), 8.06 (s, 1H), 8.17 (s, 1H)
126.84, 127.30, 130.58, 131.04, 134.19, 
136.05, 145.79, 155.81
19 7.36 (m, 5H), 7.49 (m, 4H), 8.06 (s, 1H) 126.84, 127.30, 130.58, 131.04, 134.19, 136.05, 145.79, 155.81
20 7.60 (t, 2H, J = 7.8), 7.70 (d, 1H, J = 7.8), 8.12 (d, 1H, J = 7.8), 8.21 (s, 1H), 8.31 (s, 1H)
124.17, 125.83, 127.15, 130.29, 132.20, 
134.95, 145.92, 123.12, 155.74
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H from imine, since this position is highly deshielded due to the induced anisotropy gene-
rated by the bound aromatic ring and the imine double bond. In 13C NMR spectra, the 
signal related to the imine carbon is usually seen around d 145 ppm, whereas the signal 
ranging from d 155 to 175 ppm is associated with the highly deshielded quaternary carbon 
of guanidine moiety.
The cell lines were exposed to derivatives guanylhydrazones (0–5 mmol L–1) and pos-
itive control: doxorubicin (5 μmol L–1) for 72 hours. Experiments were performed in tripli-
cate.
Phenylaminoguanidine 15 exhibits a very low cytotoxic activity, only 20 % inhibition 
of tumor cell lines at 5 mmol L–1. Introduction of an electron-donor group such as hydroxyl 
or methoxyl 4, 5, 6 and 7 at ortho- and/or para-position did not increase the cytotoxic activ-
ity. However, bridging between two groups in 9 induced a slight increase in activity to-
wards the MDA-MB-435 cell line (Table II).
Replacement of the electron-donor group by electron-withdrawing polar groups such 
as nitrile 3 or formyl 11 showed no signifi cant improvement in potency relative to the par-
ent phenyl group. Introduction of halogen atoms signifi cantly enhanced the activity, as 
seen in compounds 2, 8 and 18.
Compound 6 has shown higher selectivity against MDA-MB-435 than the other two 
cell lines. This facts, may be related to hydroxyl at position 3 in the phenyl ring, showing 
superior activity compared to the compound 4.
A signifi cant increase in cytotoxic activity was observed, when chlorine was intro-
duced in para- position, since compound 2 was found more potent than 18 (meta-position). 
However, disubstituted 3,4-dichloro analogue 17 led to bett er activity, with 100 % inhibi-
tion of tumor cell lines at 5 mmol L–1. Interestingly, guanabenz (trade name, Wintensy®) 12, 
a drug developed as an alpha-2 adrenergic agonist was signifi cantly less active than com-
pound 19.
Introduction of a second phenyl ring at para- 14 or ortho- 19 position led to a set of more 
potent compounds. This eff ect highlights the importance of the lipophilic character, which 
probably plays an important role in cytotoxic activity. In this sense, compound 10 was also 
highly active, since the presence of the bulky tert-butyl groups increased lipophilic char-
acter to the molecule, resulting in the best compound of the series.
Finally, the replacement of the phenyl ring by a heteroaromatic ring as in 1 and 13 led 
to activity decrease compared to compound 15.
The most powerful compounds recognized in cytotoxic assays against human cancer 
cell lines at 5 mmol L–1 (Table II) were tested to obtain IC50 values, which were compared to 
those of doxorubicin (control), as shown in Table III. Each assay was carried out in dupli-
Scheme 1
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  1 – – 24.0 71 
  2 72.9 80.2 72.1 71 
  3 25.4 38.8 28.6 89 
  4 3.5 0.2 25.3 93 
  5 – 17.3 19.5 98 
  6 – 32.4 2.5 92 
  7 – – 11.5 95 
  8 67.3 81.6 58.0 83 
  9 – 53.2 19.6 81 
10 97.2 92.6 97.8 85 
11 10.3 16.3 26.2 71 
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cate and the means and respective confi dence intervals were obtained by nonlinear regres-
sion analyses.
In order to investigate the eff ect of guanylhydrazone derivatives on non-tumor cells, 
compounds 10, 14, 17 and 19 were evaluated on macrophages J774 aft er 24 hours of incuba-
12 45.2 15.3 51.9 89 
13 42.1 29.8 52.0 91 
14 100 100 100 90 
15 28.3 26.5 24.7 89 
16 43.1 48.6 37.8 92 
17 100 100 100 92 
18 52.1 46.0 52.0 91 
19 96.9 95.2 93.8 92 
20 52.7 33.7 45.5 88 
Doxorubicin 97.3 96.9 87.6 – –
a Average value for 5 μmol L–1 concentration (n = 3). 
– Not active
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tion and data obtained are displayed in Fig. 2. Results suggest that 10 shows low toxicity 
to non-tumor cells, because it is only able to decrease cell viability at a high concentration 
of 1 mmol L–1. The other three compounds, 14, 17 and 19, showed higher cytotoxicity for 
non-tumor cells since they reduced cell viability at all tested concentrations (10, 100 and 
1000 mmol L–1). This confi rms that compound 10 acts selectively on tumor cell lines and 
bears the most promising profi le regarding cytotoxic activity.
Fig. 2. J774 cell viability aft er 24 h in the presence of selected guanylhydrazone compounds (mean ± 
SD, n = 2).
Table III. IC50 values of guanylhydrazone derivatives in three human cancer cell lines
Cell line
IC50 (μmol L–1)
10 14 17 19 Doxorubicin 
MDA-MB-435 3.4 4.2 0.4 9.8 0.8 
HCT-8 3.9 1.8 0.7 3.6   0.02 
SF-295 3.9 2.0 0.6 6.0 0.3 
CONCLUSIONS
The results reported in this study indicate that lipophilic guanylhydrazones 10, 14, 17 
and 19 showed the highest cytotoxic activity against diff erent human cancer cell lines. 
Compound 10 showed higher selectivity towards tumor cell lines and therefore it may be 
considered promising for the development of novel cytotoxic agents based on this scaff old.
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